Aspire BioPharma is trading at $7.63 (+7.31%) after reporting second-quarter results with a narrower net loss.
- Second-quarter sales were $63,104, while net loss improved to $1.27 million from $1.98 million a year earlier.
- Six-month net loss narrowed to $4.49 million from $17.92 million, while sales reached $91,457. The earnings release was published after the August 13 close, making it the clearest identified catalyst for the August 14 gain.